- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05472779
Periuretral vs intravaginal östrogen för att förebygga återkommande urinvägsinfektioner (TAPER)
Periuretral vs intravaginal östrogen för förebyggande av återkommande urinvägsinfektioner: TAPER (tekniker för att applicera vaginalt östrogen för att förhindra återkommande urinvägsinfektioner) Trial
Due to rising antibiotic resistance, there has been a focus on non-antibiotic prophylactic measures for postmenopausal patients with recurrent urinary tract infections (rUTI), one of which is the safe and efficacious option of vaginal estrogen therapy. Standard application of vaginal estrogen cream entails intravaginal application of the cream twice a week, but some providers counsel patients with rUTI to apply a small, pea-sized amount to the periurethral area. This ideally reduces the amount of vaginal estrogen used while attaining a similar effect. However, to date, there is no data to prove that the periurethral technique of application is similar or non-inferior to intravaginal application in preventing UTI.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
Pennsylvania
-
Cranberry Township, Pennsylvania, Förenta staterna, 16066
- UPMC Lemieux Sports Complex
-
Erie, Pennsylvania, Förenta staterna, 16550
- UPMC Hamot
-
Pittsburgh, Pennsylvania, Förenta staterna, 15213
- University of Pittsburgh Medical Center-Magee Womens Hospital
-
Pittsburgh, Pennsylvania, Förenta staterna, 15237
- UPMC Passavant-McCandless
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Postmenopausal (definition: No menses for 1 or more years or surgical menopause (bilateral oophorectomy). If there is a past history of hysterectomy, patient must be age 56 or older (95th percentile for age at menopause) or have laboratory evidence of menopause (ie. FSH >30)
- Meets criteria for recurrent urinary tract infections (UTIs) with 2 or more UTI in 6 months or 3 or more UTI in 1 year
- May include patients who used vaginal estrogen previously if they have stopped use for 3 or more months prior to inclusion into study.
- Patients must be recommended vaginal estrogen as part of normal clinical care for prevention of recurrent UTI
Exclusion Criteria:
- Current use of vaginal or oral estrogen products
- Inability or refusal to use vaginal estrogen
- Daily antibiotic use
- Significant vaginal stenosis (eg. due to lichen sclerosis, radiation or obliterative prolapse surgery) that would prohibit use of a vaginal applicator (ie. genital hiatus <1cm)
- Inability to use vaginal applicator and without caregiver who can administer (eg. provider-managed pessary use, significant arthritis)
- Frequent (1x weekly or more frequent) use of bladder instillations containing an antibiotic
- Known hydronephrosis as a result of incomplete bladder emptying
- Use of intermittent or indwelling urinary catheterization
- Known bladder stones, mesh erosion into bladder, or foreign object in bladder
- Unable to consent for self
- Active treatment for an estrogen-dependent malignancy
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Intravaginal Estrogen Application
Intravaginal application of 1 gram estradiol cream at bedtime twice a week for 6 months |
The control group will apply 1 gram estradiol cream intravaginally using an applicator. |
|
Experimentell: Periurethral Estrogen Application
Periurethral application of 0.5 gram estradiol cream at bedtime twice a week for 6 months |
The experimental group will apply estradiol cream in a different location (periurethral) and at a smaller dose (0.5 gram) compared to the control group. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Percentage of Participants Who Are UTI-free at 6 Months
Tidsram: 6 months
|
The primary outcome was the percentage of participants who were UTI-free at 6 months after study drug initiation. |
6 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change From Baseline in Urinary Symptoms at 6 Months
Tidsram: Baseline, 6 months
|
Questionnaire assessment of urinary symptoms and symptom distress (Urogenital Distress Inventory, Short Form), total score range 0-100 with higher numbers representing worse urinary symptoms |
Baseline, 6 months
|
|
Change From Baseline in Sexual Function at 6 Months
Tidsram: Baseline, 6 months
|
Questionnaire assessment of sexual function (Female Sexual Function Index-6) with scores ranging from 2 to 30, with 19 and below denoting sexual dysfunction. |
Baseline, 6 months
|
|
Change From Baseline in Vaginal pH at 6 Months
Tidsram: Baseline, 6 months
|
Assessment using pH strips during pelvic examination |
Baseline, 6 months
|
|
Participant Experience With Study Drug
Tidsram: 6 months
|
Agreement with the statement: "I am satisfied with the estrogen cream." (Positive response of "agree" or "strongly agree" on 5-point Likert Scale) |
6 months
|
|
Vaginal Maturation Value
Tidsram: 3 months
|
Vaginal maturation value at 3 months (score 0-100, higher values correlating with greater vaginal estrogenization) |
3 months
|
|
Average Amount of Estrogen Used Per Tube
Tidsram: 6 months
|
Study drug tubes were weighed at baseline and then at follow-up visits (weight in grams) and the average amount of study drug used per tube was calculated. |
6 months
|
|
Percentage of Participants With Lactobacillus Crispatus Positive Vaginal Specimens
Tidsram: 6 months
|
Lactobacillus crispatus is a species of Lactobacillus known to assist with UTI prevention through the maintenance of an acidic environment. It generally is elevated in the vagina in the presence of estrogen. |
6 months
|
|
Percentage of Participants With E. Coli Positive Vaginal Specimens
Tidsram: 6 months
|
E. coli is a common uropathogen and thus was investigated in the pilot translational sub-aim of this research study. |
6 months
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Stephanie W Zuo, MD, University of Pittsburgh Medical Center
Publikationer och användbara länkar
Allmänna publikationer
- Zuo SW, Bradley M, Mowers EE, Zyczynski HM, Hillier SL, Ackenbom MF. Periurethral versus intravaginal application of vaginal estrogen for the prevention of urinary tract infections in postmenopausal women: Design of a randomized non-inferiority trial. Contemp Clin Trials. 2025 Jun;153:107893. doi: 10.1016/j.cct.2025.107893. Epub 2025 Mar 30.
- Zuo SW, Mowers EE, Hem S, Bradley M, Zyczynski HM, Hillier SL, Ackenbom MF. Vaginal Estrogen Application Techniques for Prevention of Urinary Tract Infection: A Randomized Trial. Obstet Gynecol. 2026 Jul 27. doi: 10.1097/AOG.0000000000006376. Online ahead of print.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- STUDY22010147
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .